首页> 外文期刊>European review for medical and pharmacological sciences. >Simultaneous administration of human acidic and recombinant less acidic follicle-stimulating hormone for ovarian stimulation improves oocyte and embryo quality, and clinical outcome in patients with repeated IVF failures
【24h】

Simultaneous administration of human acidic and recombinant less acidic follicle-stimulating hormone for ovarian stimulation improves oocyte and embryo quality, and clinical outcome in patients with repeated IVF failures

机译:同时给予人酸性和重组弱酸性卵泡刺激素以刺激卵巢,可改善卵母细胞和胚胎质量,并改善IVF反复失败患者的临床结局

获取原文
获取外文期刊封面目录资料

摘要

BACKGROUND: Ovarian stimulation is an integral procedure in assisted reproduction treatment. It is achieved by the administration of exogenous gonadotropins to increase follicular recruitment and oocyte yield. Optimization of ovarian stimulation is an essential prerequisite for the success of IVF treatment. AIM: This study aimed to evaluate the effect of a combined stimulation protocol of human FSH and recombinant FSH, simultaneously administered, on oocyte and embryo quality and clinical outcome. PATIENTS AND METHODS: In a prospective randomized study 197 infertile patients with a history of previous IVF failures for at least 3-5 attempts, were enrolled for an in vitro fertilization treatment. All patients had a standard down-regulation with GnRH analog and were then stimulated with FSH. The patients were matched into three groups: group A (no = 66) received human FSH combined with recombinant FSH in equal doses, simultaneously administered; group B (no = 67) received human FSH alone and group C (no = 64) received recombinant FSH alone. RESULTS: There were significantly higher pregnancy (p < 0.04) and implantation rates (p < 0.03) in favor of group A (hFSH/rFSH) compared to groups B (hFSH) and C (rFSH). A significant increase in the proportion of mature metaphase II oocytes (p < 0.002) and grade 1 embryos (p < 0.03) was observed in group A with respect to group B and C. Significantly higher delivery rate (p < 0.01) was achieved in group A compared to groups B and C. No significant differences were observed between groups regarding miscarriage rate and risk of ovarian hyperstimulation syndrome. CONCLUSIONS: The results show that the combination of human and recombinant FSH for ovarian stimulation may produce a positive effect on follicular development as it improve oocyte quality, embryo development, and ultimately clinical outcome.
机译:背景:卵巢刺激是辅助生殖治疗中不可或缺的步骤。通过施用外源促性腺激素来增加卵泡募集和卵母细胞产量来实现。优化卵巢刺激是IVF治疗成功的重要前提。目的:本研究旨在评估同时施用人FSH和重组FSH的联合刺激方案对卵母细胞和胚胎质量以及临床结果的影响。患者和方法:在一项前瞻性随机研究中,招募了197名有IVF失败史且至少进行3-5次尝试的不育患者,进行了体外受精治疗。所有患者均被GnRH类似物下调,然后被FSH刺激。将患者分为三组:A组(无= 66)同时接受等剂量的人FSH和重组FSH联合治疗; B组(无= 67)仅接受人FSH,C组(无= 64)仅接受重组FSH。结果:与B组(hFSH)和C组(rFSH)相比,A组(hFSH / rFSH)的妊娠率(p <0.04)和着床率(p <0.03)显着更高。与B和C组相比,A组的成熟中期II卵母细胞(p <0.002)和1级胚胎(p <0.03)的比例显着增加。 A组与B组和C组相比。两组之间在流产率和卵巢过度刺激综合征风险方面没有观察到显着差异。结论:结果显示,人和重组FSH联合用于卵巢刺激可能会改善卵泡发育,改善卵母细胞质量,胚胎发育并最终改善临床结局,从而对卵泡发育产生积极影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号